LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

CRISPR Therapeutics AG

Geschlossen

BrancheGesundheitswesen

47.4 1.41

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

46.13

Max

47.54

Schlüsselkennzahlen

By Trading Economics

Einkommen

-99M

-136M

Verkäufe

-34M

865K

EPS

-1.58

Gewinnspanne

-15,722.081

Angestellte

393

EBITDA

-84M

-144M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+47% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

1. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

685M

3.9B

Vorheriger Eröffnungskurs

45.99

Vorheriger Schlusskurs

47.4

Nachrichtenstimmung

By Acuity

22%

78%

45 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

CRISPR Therapeutics AG Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

26. Sept. 2024, 16:08 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Pfizer's Strategy Looks Shakier After Sickle-Cell Disappointment -- Barrons.com

26. Sept. 2024, 14:20 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

Peer-Vergleich

Kursveränderung

CRISPR Therapeutics AG Prognose

Kursziel

By TipRanks

47% Vorteil

12-Monats-Prognose

Durchschnitt 68.65 USD  47%

Hoch 105 USD

Tief 35 USD

Basierend auf 20 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für CRISPR Therapeutics AG – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

20 ratings

13

Buy

7

Halten

0

Sell

Technischer Score

By Trading Central

33.5 / 38.27Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

45 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.